These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18294981)

  • 41. New anticoagulants offer options beyond warfarin to reduce stroke risk.
    Mitka M
    JAMA; 2012 Nov; 308(17):1727-8. PubMed ID: 23117757
    [No Abstract]   [Full Text] [Related]  

  • 42. Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants.
    Turagam MK; Velagapudi P; Flaker GC
    Clin Interv Aging; 2015; 10():1431-44. PubMed ID: 26366064
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation.
    Wilson MR; Parakramawansha R; Quinn TJ; Tait RC
    Thromb Haemost; 2016 Aug; 116(3):578-80. PubMed ID: 27307147
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
    Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
    Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease.
    Kampouraki E; Kamali F
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):789-797. PubMed ID: 28635328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal.
    Potpara TS; Lip GYH; Blomström-Lundqvist C; Chiang CE; Camm AJ
    Am J Med; 2017 Jul; 130(7):773-779. PubMed ID: 28344142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stroke in heart failure: atrial fibrillation revisited?
    Pullicino P; Homma S
    J Stroke Cerebrovasc Dis; 2010 Jan; 19(1):1-2. PubMed ID: 20123219
    [No Abstract]   [Full Text] [Related]  

  • 48. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation.
    Hussein A; Saliba W; Wazni OM
    Cleve Clin J Med; 2015 Dec; 82(12 Suppl 2):S11-6. PubMed ID: 26694887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dabigatran for stroke prevention in all patients with atrial fibrillation?
    Hunchuck JE; Lake JD
    Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
    [No Abstract]   [Full Text] [Related]  

  • 51. Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation.
    Bungard TJ; Ghali WA; McAlister FA; Buchan AM; Cave AJ; Hamilton PG; Mitchell LB; Shuaib A; Teo KK; Tsuyuki RT
    CMAJ; 2001 Aug; 165(3):301-2. PubMed ID: 11517646
    [No Abstract]   [Full Text] [Related]  

  • 52. Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults - a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing.
    Sommerauer C; Schlender L; Krause M; Weißbach S; Rieckert A; Martinez YV; Reeves D; Renom-Guiteras A; Kunnamo I; Sönnichsen A
    BMC Geriatr; 2017 Oct; 17(Suppl 1):223. PubMed ID: 29047348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Warfarin should not be recommended to anyone with atrial fibrillation].
    Samuelsson O; Saeed A
    Lakartidningen; 2017 May; 114():. PubMed ID: 28510240
    [No Abstract]   [Full Text] [Related]  

  • 54. Atrial fibrillation: stroke prevention in older adults.
    Quinn GR; Fang MC
    Clin Geriatr Med; 2012 Nov; 28(4):617-34. PubMed ID: 23101573
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [New treatments for stroke and thromboembolism prevention in atrial fibrillation].
    Shiyovich A; Khalameizer V; Katz A
    Harefuah; 2014 Jan; 153(1):32-8, 64. PubMed ID: 24605405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stroke prevention in atrial fibrillation patients.
    Marinigh R; Lip GY; Lane DA
    Expert Opin Pharmacother; 2010 Oct; 11(14):2331-50. PubMed ID: 20718589
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
    Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
    Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of thromboembolic events in atrial fibrillation.
    Koefoed BG; Gulløv AL; Petersen P
    Thromb Haemost; 1997 Jul; 78(1):377-81. PubMed ID: 9198182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists.
    Fauchier L; Angoulvant D; Lip GY
    Europace; 2015 May; 17(5):671-3. PubMed ID: 25829474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.